Dr. Iyengar on Trastuzumab Deruxtecan in HER2-Low Breast Cancer

Video

Neil M. Iyengar, MD, discusses the use of fam-trastuzumab deruxtecan-nxki in HER2-low breast cancer.

Neil M. Iyengar, MD, medical oncologist, Breast Cancer, Memorial Sloan Kettering Cancer Center, discusses the use of fam-trastuzumab deruxtecan-nxki (Enhertu) in HER2-low breast cancer.

HER2-low breast cancer is a newer phenotype within this disease space and other cancers, Iyengar says. Trastuzumab deruxtecan has generated activity in early-phase studies involving patients with HER2-low expressing cancers, Iyengar says. Notably, patients with triple-negative breast cancer or estrogen receptor- (ER) positive, HER2-negative breast cancer that has progressed or become endocrine insensitive are typically treated with chemotherapy, Iyengar explains.

Trastuzumab deruxtecan could represent a new therapeutic approach for patients categorized into a subgroup of low expression of HER2, Iyengar says. Future data could lead to the registration of drugs like trastuzumab deruxtecan in this space, Iyengar concludes.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Video 1 - "HR+/HER2- Early-Stage Breast Cancer: Background and Risk Stratification "
Minesh Mehta, MD
Ruben Olivares, MD